INTRA-AORTIC BALLOON PUMP DOES NOT IMPROVE SURVIVAL IN PATIENTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION COMPLICATED BY CARDIOGENIC SHOCK: DATA FROM A LARGE SINGLE CENTER REGISTRY  by De Ferrari, Gaetano M. et al.
A173
JACC March 17, 2015
Volume 65, Issue 10S
Acute Coronary Syndromes
intRa-aoRtic balloon pump does not impRove suRvival in patients with st segment 
elevation myocaRdial inFaRction complicated by caRdiogenic shock: data FRom a 
laRge single centeR RegistRy
Poster Contributions
Poster Hall B1
Sunday, March 15, 2015, 3:45 p.m.-4:30 p.m.
Session Title: From Cardiac Arrest, LV Failure to Myocardium Salvage
Abstract Category: 2. Acute Coronary Syndromes: Clinical
Presentation Number: 1209-056
Authors: Gaetano M. De Ferrari, Stefano Cornara, Alberto Somaschini, Raniero Covi, Andrea Baldo, Rita Camporotondo, Gabriele Crimi, 
Marco Ferlini, Silvia Pica, Maurizio Ferrario, Dept. of Cardiology Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, University of 
Pavia, Pavia, Italy
background:  Recent evidence from a randomized clinical trial has re-evaluated the benefit of intra-aortic balloon pump (IABP) in patients 
with STEMI complicated by cardiogenic shock, leading to a downgrading of the recommendation level in the international guidelines. The 
aim of our study was to evaluate the effects of IABP on short and long-term mortality in a large homogeneous single-center population of 
consecutive STEMI patients complicated by cardiogenic shock.
methods:  Our registry included 1787 patients undergoing primary PCI for STEMI in our department from 2005 to 2013. The presence 
of systolic blood pressure < 90 mmHg within 24 hours from admittance and signs of impaired end organ perfusion needing mechanical 
or catecholamine support qualified for cardiogenic shock (CS); the need for infusive catecholamine support within 48 h and the presence 
of anterior STEMI and/or left ventricular ejection fraction (LVEF) < 30% qualified for high-risk (HR) CS. We performed univariate and 
multivariate analysis.
Results:  CS, with the inclusive definition, occurred in 196 patients (11%), HR CS in 97 of them (50%). IABP was used in 68% of CS 
and 73% of HR CS group. In the overall CS group there was a trend toward reduced 30 days and 30 months mortality among patients 
with IABP but multivariable analysis showed no effect of IABP on either mortality (HR 1.0, 95%CI 0.38-2.83 and 0.83, 95%CI 0.39-1.77, 
respectively) after adjusting for LVEF, age and creatinine at admission. In HR-CS, IABP use was associated with decreased short- (28% 
vs 50%, p=0.05) and long-term (35% vs 64%, p=0.016) mortality, but was also not found to be a significant independent predictor at 
multivariable analysis (HR 1.02 95%CI 0.25-4.61 and 0.5 95%CI 0.18-1.39, respectively).
conclusion:  IABP in STEMI patients complicated by CS does not improve survival in real life, although an improvement was observed in 
univariate analysis in a HR subset of patients. The present data are in agreement with the recommendation of avoiding a generalized use 
of IABP in patients with CS but suggest the opportunity to prospectively assess its potential value in an appropriately defined group of high 
risk CS patients.
